SarCaBon: a randomised phase II trial of saracatinib versus placebo for cancer-induced bone pain
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2019
Price : $35 *
At a glance
- Drugs Saracatinib (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- Acronyms SarCaBon
- 12 Apr 2018 Status changed from active, no longer recruiting to completed.
- 04 May 2017 Planned End Date changed from 31 Jul 2017 to 1 Mar 2018.
- 04 May 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.